Body distribution of polysorbate‐80 and doxorubicin-loaded [¹⁴C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats

References

• Alyautdin RN, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin absorbed on the surface of polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 1995; 41: 44–48
   Web of Science ®Google Scholar
• Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997; 14: 325–328
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: An in situ brain perfusion study. J Microencapsul 1998; 15: 67–74
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly-(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target 2001; 9: 209–221
   PubMed Web of Science ®Google Scholar
• Behan N, Birkinshaw C, Clarke N. Poly n-butyl cyanoacrylate nanoparticles: A mechanistic study of polymerisation and particle formation. Biomaterials 2001; 22: 1335–1344
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54: 631–651
   PubMed Web of Science ®Google Scholar
• Brigger I, Morizet J, Couvreur P. Negative preclinical results with stealth nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. J Control Release 2004; 100: 29–40
   PubMed Web of Science ®Google Scholar
• Borchard G, Kreuter J. Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. J Drug Target 1993; 1: 15–19
   PubMed Web of Science ®Google Scholar
• de Verdiere AC, Dubernet C, Nemati F, Soma E, Appel M, Ferte J, Bernard S, Puisieux F, Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action. Br J Cancer 1997; 76: 198–205
   PubMed Web of Science ®Google Scholar
• Gipps EM, Arshady R, Kreuter J, Groscurth P, Speiser PP. Distribution of polyhexyl cyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. J Pharm Sci 1986; 75: 256–258
   PubMed Web of Science ®Google Scholar
• Gipps EM, Groscurth P, Kreuter J, Speiser PP. Distribution of polyhexylcyanoacrylate nanoparticles in nude mice over extended times and after repeated injection. J Pharm Sci 1988; 77: 208–209
   PubMed Web of Science ®Google Scholar
• Granholm AC, Albeck D, Backman C, Curtis M, Ebendal T, Friden P, Henry M, Hoffer B, Kordower J, Rose GM, Soderstrom S, Bartus RT. A non-invasive system for delivering neural growth factors across the blood-brain barrier: A review. Rev Neurosci 1998; 9: 31–55
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999; 16: 1564–1569
   PubMed Web of Science ®Google Scholar
• Hu YP, Jarillon S, Dubernet C, Couvreur P, Robert J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother Pharmacol 1996; 37: 556–560
   PubMed Web of Science ®Google Scholar
• Kreuter J. Evaluation of nanoparticles as drug-delivery systems II: Comparison of the body distribution of nanoparticles with the body distribution of microspheres (diameter greater than 1 micron), liposomes, and emulsions. Pharm Acta Helv 1983a; 58: 217–226
   PubMedGoogle Scholar
• Kreuter J. Evaluation of nanoparticles as drug-delivery system I: Preparation methods. Pharm Acta Helv 1983b; 58: 196–209
   Google Scholar
• Kreuter J. Physicochemical characterization of polyacrylic nanoparticles. Int J Pharm 1983c; 14: 43–58
   Web of Science ®Google Scholar
• Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995; 674: 171–174
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65–81
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002; 10: 317–325
   PubMed Web of Science ®Google Scholar
• Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002; 28: 1–13
   PubMed Web of Science ®Google Scholar
• Lück M. 1997. Plasmaproteinadsorption als möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffapplikation mit partikulären Trägern. PhD thesis, Freie Universität Berlin, pp. 14–24, 137–154.
   Google Scholar
• Neuwelt EA, Barnett PA, Hellstrom KE, Hellstrom I, McCormick CI, Ramsey FL. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med 1994; 35: 1831–1841
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Peptide drug delivery to the brain. Raven Press, New York 1991; 52–53
   Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 2003; 3: 90–105, 51
   PubMedGoogle Scholar
• Roullin VG, Deverre JR, Lemaire L, Hindre F, Venier-Julienne MC, Vienet R, Benoit JP. Anti-cancer drug diffusion within living rat brain tissue: An experimental study using [(3)H](6)-5-fluorouracil-loaded PLGA microspheres. Eur J Pharm Biopharm 2002; 53: 293–299
   PubMed Web of Science ®Google Scholar
• Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004; 109: 759–767
   PubMed Web of Science ®Google Scholar
• Schröder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res 1996; 710: 121–124
   PubMed Web of Science ®Google Scholar
• Schröder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 1998; 87: 1305–1307
   PubMed Web of Science ®Google Scholar
• Tsuji A. The specific mechanism for transporting drugs into the brain blood-brain barrier and the drug delivery to the CNS, DJ Begley, MW Bradbury, J Kreuter. Marcel Dekker, New York 2000; 121–144, Secific mechanism forortgs drugs to the bta
   Google Scholar
• Tröster SD, Müller U, Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm 1990; 61: 85–100
   Web of Science ®Google Scholar
• Tröster SD, Kreuter J. Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles. J Microencapsul 1992; 9: 19–28
   PubMed Web of Science ®Google Scholar
• von Heijne G, Gavel Y. Topogenic signals in integral membrane proteins. Eur J Biochem 1988; 174: 671–678
   PubMedGoogle Scholar
• von Heijne G. Membrane protein structure prediction. Hydrophobicity anlysis and the positive-inside rule. J Mol Biol 1992; 225: 487–494
   PubMed Web of Science ®Google Scholar